HD-OPM Archive
Topics › GLP-1 drugs (semaglutide, tirzepatide)

GLP-1 drugs and cancer: ASCO studies suggest lower risk and progression (observational)

Louis Nervegna · Jun 06, 2026 · ♥ 8 reactions · 2 comments · original Facebook post
GLP-1 drugs (semaglutide, tirzepatide)CancerWeight, visceral & liver fat
AI summary & key facts

Louis shares a summary of a Washington Post article on 40+ ASCO studies of GLP-1 drugs and cancer. Observational data hint at lower breast cancer risk, better survival and less progression to stage IV, but these are associations.

#glp1HD #cancerHD

Research cited

The GLP-1 cancer story keeps getting more interesting.

These drugs started as diabetes medications. Then they transformed obesity treatment. Now researchers are asking a bigger question:

Could GLP-1 medications also reduce cancer risk, slow cancer progression, or even improve the effectiveness of cancer treatments?

A new Washington Post article highlights several studies presented at ASCO looking at GLP-1 drugs such as Ozempic, Wegovy, and Mounjaro in cancer prevention, progression, and survival. Science around glp drugs cancer is suddenly getting lot more interesting (washingtonpost.com)

The numbers are worth paying attention to:

That is a lot of signal.

But it is not proof.

Most of these studies are observational. That means they can show associations, but they cannot prove that GLP-1 drugs prevent cancer or improve cancer survival.

There is also an important caution: randomized trial data so far have not clearly proven that GLP-1 drugs reduce cancer risk. Many of those trials were not designed to study cancer outcomes and had limited follow-up, but the distinction matters.

Another nuance: some studies compare GLP-1 drugs against insulin. Since insulin itself may have cancer-promoting biology in some settings, that comparison could make GLP-1s look more favorable. When GLP-1s are compared with metformin or SGLT2 inhibitors, the advantage may be smaller or may disappear.

So no, I would not call GLP-1s cancer-prevention drugs today.

And I would not recommend them specifically to treat cancer.

But I also would not ignore this signal.

The most interesting question is whether the benefits are simply from weight loss, or whether GLP-1 drugs are doing something deeper: improving insulin resistance, lowering inflammation, altering immune signaling, changing the tumor microenvironment, or possibly making immunotherapy and targeted therapy work better.

Cancer is not only a genetic disease.

It is also influenced by metabolism, inflammation, hormones, immune function, insulin resistance, visceral fat, and the environment around the tumor.

That may be the real lesson here.

GLP-1 drugs may end up being one of the most important metabolic therapies of our time.

Not proven cancer drugs.

But absolutely worth studying.

No photo description available.
← newer: Largest collagen review (113 trials): helps skin and osteoarolder: Paricalcitol plus chemo safe in 36 pancreatic cancer patient →